Sino Biopharmaceutical to Acquire Conflux for Blockchain Expansion

Sino Biopharmaceutical Limited, a Hong Kong-listed company, has announced its intention to acquire full ownership of Conflux, a blockchain technology development firm. The company entered into a Memorandum of Understanding with the seller, Northwestern Foundation, and Conflux on June 30, 2025. This potential acquisition is contingent upon the target company completing the acquisition of Conflux's assets as per an agreement with Sino Biopharmarmaceutical Limited.

Conflux, a limited company registered in Hong Kong, China, specializes in blockchain technology development. The target company, which is intended to be a limited company registered in the Cayman Islands and wholly owned by the seller, is a key player in this potential acquisition. Sino Biopharmaceutical Limited is actively seeking new business opportunities to diversify its revenue streams and enhance its performance. The company is planning to expand its business into the blockchain technology sector, entering the digital innovation industry.

By entering into the Memorandum of Understanding, Sino Biopharmaceutical Limited has demonstrated its commitment to entering the digital innovation industry through this potential acquisition. The company believes that this move will not only diversify its business but also introduce new profit growth drivers. This strategic plan aligns with the company's goal of enhancing performance and exploring new business opportunities.